Guilherme H. Cantuaria
Obstetrics and Gynecology
960 Johnson Ferry Rd Ste 130
Atlanta, GA 30342
Atlanta, GA 30342
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.
Journal: Gynecologic oncology
Published: March 19, 2026
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 19, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 03, 2024
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Journal: Nature medicine
Published: September 23, 2024
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Journal: The New England journal of medicine
Published: March 27, 2023
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 09, 2021
Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532].
Journal: Gynecologic oncology reports
Published: September 05, 2020
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Journal: Gynecologic oncology reports
Published: November 18, 2019
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study.
Journal: Cancers
Published: June 13, 2019
Lay navigation across the cancer continuum for older cancer survivors: Equally beneficial for Black and White survivors?
Journal: Journal of geriatric oncology
Published: June 12, 2018
Last Updated: 09/26/2026